SCHEMBL16071685

SCHEMBL16071685

CCN1CCN(c2ccc(N)c(NC(=O)OC(C)(C)C)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.51
RAD52 P43351 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GFER P55789 1/20 0.44
HDAC1 Q13547 3/20 0.43
FLT3 P36888 1/20 0.43
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
LGMN Q99538 1/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21600773 0.89 AAK1 (0.39) GAARAD52SMN1; SMN2MAPTKDM4E
SCHEMBL12466602 0.87 MAPT (0.51) GAAMAPTKDM4EHDAC1MEN1
SCHEMBL21600746 0.87 HDAC1 (0.52) GAASMN1; SMN2MAPTKDM4EGFER
SCHEMBL16071545 0.86 HDAC1 (0.51) GAASMN1; SMN2MAPTKDM4EGFER
SCHEMBL21600816 0.85 CASP6 (0.49) MAPTGFERHDAC1MEN1KMT2A
SCHEMBL30002368 0.85 CASP6 (0.49) MAPTGFERHDAC1MEN1KMT2A
SCHEMBL23606833 0.84 AAK1 (0.43) GAAMAPTKDM4EHDAC1AAK1
SCHEMBL30043568 0.84 AAK1 (0.43) GAAMAPTKDM4EHDAC1AAK1
SCHEMBL16071571 0.84 RAB9A (0.44) GAASMN1; SMN2MAPTKDM4EHDAC1
SCHEMBL18036475 0.84 LGMN (0.50) SMN1; SMN2MAPTKDM4EHDAC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582654-B2 Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2026-03-24 US disclosed
EP-4083021-B1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2025-07-02 EP disclosed
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-04-20 US disclosed
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-04-20 US disclosed
CN-112313207-B Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof 北京赛特明强医药科技有限公司 2023-02-14 CN disclosed
EP-4083021-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2022-11-02 EP disclosed
CN-113087671-B Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof 北京赛特明强医药科技有限公司 2022-10-21 CN disclosed
US-20220332687-A1 HETEROARYL COMPOUNDS AND USES THEREOF SANOFI (FR) 2022-10-20 US disclosed
EP-3943087-A1 HETEROARYL COMPOUNDS AND USES THEREOF Celgene CAR LLC (BM) 2022-01-26 EP disclosed
EP-2968337-B1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2021-07-21 EP disclosed
US-10189794-B2 Heteroaryl compounds and uses thereof CELGENE CAR LLC (BM) 2019-01-29 US disclosed
US-20180022713-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2018-01-25 US disclosed
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-09-21 US disclosed
US-9695132-B2 Heteroaryl compounds and uses thereof CELGENE CAR LLC (BM) 2017-07-04 US disclosed
US-9663524-B2 Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors CELGENE CAR LLC (BM) 2017-05-30 US disclosed
US-20160221966-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-08-04 US disclosed
US-9321786-B2 Heteroaryl compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2016-04-26 US disclosed
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-02-18 US disclosed
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF SANOFI (FR) 2014-10-02 US disclosed
WO-2014144737-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF FGFR4, FGFR1, WEE1 GAA 3528/4885RAD52 4495/4885SMN1; SMN2 4545/4885
US-20140296233-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 GAA 172/4885RAD52 4188/4885SMN1; SMN2 2352/4885
US-20220332687-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 GAA 172/4885RAD52 4188/4885SMN1; SMN2 2352/4885
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC GAA 2218/4885RAD52 3345/4885SMN1; SMN2 4743/4885
US-12582654-B2 Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof FGFR4, FGFR3, FGFR1 GAA 4446/4885RAD52 4379/4885SMN1; SMN2 4538/4885
US-10189794-B2 Heteroaryl compounds and uses thereof ABCG2, CYP3A43, CYP3A5 GAA 172/4885RAD52 4188/4885SMN1; SMN2 2352/4885
US-20160221966-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 GAA 172/4885RAD52 4188/4885SMN1; SMN2 2352/4885
US-20180022713-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 GAA 172/4885RAD52 4188/4885SMN1; SMN2 2352/4885
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC GAA 2218/4885RAD52 3345/4885SMN1; SMN2 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.